

Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Jolanda van der Velden^{1,2*}, Carlo G. Tocchetti³, Gilda Varricchi³, Anna Bianco^{3,4}, Vasco Sequeira¹, Denise Hilfiker-Kleiner⁵, Nazha Hamdani⁶, Adelino F. Leite-Moreira⁷, Manuel Mayr⁸, Ines Falcão-Pires⁷, Thomas Thum^{9,10,11}, Dana K. Dawson¹², Jean-Luc Balligand¹³, and Stephane Heymans^{2,4,14}

¹Amsterdam UMC, Vrije Universiteit Amsterdam, Physiology, Amsterdam Cardiovascular Sciences, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; ²Netherlands Heart Institute, Utrecht, The Netherlands; ³Department of Translational Medical Sciences, Federico II University, Naples, NA, Italy; ⁴Department of Cardiology, Maastricht University Medical Center & CARIM, Maastricht University, Maastricht, The Netherlands; ⁵Molecular Cardiology, Department of Cardiology and Angiology, Medical School Hannover, Germany; ⁶Department of Systems Physiology, Ruhr University Bochum, Bochum, Germany; ⁷Department of Surgery and Physiology, Faculty of Medicine, Cardiovascular Research Centre, University of Porto, Porto, Portugal; ⁸The James Black Centre & King's British Heart Foundation Centre, King's College, University of London, London, UK; ⁹Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany; ¹⁰National Heart and Lung Institute, Imperial College London, London, UK; ¹¹REBIRTH Excellence Cluster, Hannover Medical School, Hannover, Germany; ¹²School of Medicine & Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, UK; ¹³Pole of Pharmacology and Therapeutics, Institut de Recherche Experimentale et Clinique (IREC), and Clinique Universitaire Saint-Luc, Université catholique de Louvain, Brussels, Belgium; and ¹⁴Department of Cardiovascular Sciences, Leuven University, Leuven, Belgium

Received 18 February 2018; revised 13 April 2018; editorial decision 29 April 2018; accepted 13 June 2018; online publish-ahead-of-print 15 June 2018

Abstract

Disturbed metabolism as a consequence of obesity and diabetes may cause cardiac diseases (recently highlighted in the cardiovascular research spotlight issue on metabolic cardiomyopathies).¹ In turn, the metabolism of the heart may also be disturbed in genetic and acquired forms of hypertrophic cardiac disease. Herein, we provide an overview of recent insights on metabolic changes in genetic hypertrophic cardiomyopathy and discuss several therapies, which may be explored to target disturbed metabolism and prevent onset of cardiac hypertrophy.

Keywords

Hypertrophic cardiomyopathy • Mutations • Metabolism

This article is part of the Mini Review Series from the Varenna 2017 meeting of the Working Group of Myocardial Function of the European Society of Cardiology.

1. HCM: inefficient sarcomere contraction as primary defect

Hypertrophic cardiomyopathy (HCM) is the most frequent inherited cardiomyopathy with a recently reported prevalence of 1:200.² HCM has an extremely wide phenotypic variation. Its diverse appearance on cardiac imaging has only been recognized fully in the past decade since cardiac magnetic resonance has been introduced as the gold standard imaging assessment for diagnostic characterization and follow-up of these patients. The same genetic signature can translate into extreme cardiac morphological findings extending from an almost normal

appearance or localized (segmental) hypertrophy to significant hypertrophy affecting predominantly the septum and/or the lateral wall and/or the apex.³ Aside from the diastolic abnormalities of the hypertrophic phenotype *per se*, additional pathophysiological consequences accompany the HCM heart such as outflow tract obstruction where the mitral valve becomes involved in the acceleration of flow seen in the obstructed outflow tract. The latter may also result in mitral regurgitation, all of which contribute to the symptoms experienced by these patients. After the first identification of a sarcomeric gene mutation in 1989,^{4,5} more than 1400 mutations have been identified, mostly in genes encoding sarcomeric proteins.⁶ Most mutations (~90%) are found in the

* Corresponding author. Tel: +31 627339910; E-mail: j.vandervelden@vumc.nl

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

thick filament proteins myosin heavy chain (MyHC, *MYH7* gene) and cardiac myosin binding protein C (cMyBP-C, *MYBPC3* gene), and the thin filament protein troponin T (cTnT, *TNNT2* gene). Initial studies on mutation-induced changes in sarcomere function revealed an increase in myofilament Ca^{2+} -sensitivity as opposed to a decreased myofilament Ca^{2+} -sensitivity in dilated cardiomyopathy (DCM).^{7–11} The opposite effects on myofilament Ca^{2+} -sensitivity appears to be a consistent observation for thin filament mutations causing HCM and DCM, respectively (see also ‘Complex road from genotype to phenotype in dilated cardiomyopathies’ in the current issue),^{8,11} while the increase in myofilament Ca^{2+} -sensitivity appears to be mostly secondary to disease progression in HCM with thick filament mutations.¹² Rather than an increase in myofilament Ca^{2+} -sensitivity, a common cellular phenotype induced by HCM sarcomere mutations is an inefficient sarcomere contraction, which is attributed to diverse changes in sarcomere properties: (i) an increase in myofilament Ca^{2+} -sensitivity, which coincides with an increase in adenosine triphosphatase (ATPase) activity indicating increased adenosine triphosphate (ATP) utilization at the sarcomeres¹³; (ii) a blunted length-dependent activation, which will cause a less efficient sarcomere response to increased stress¹⁴; (iii) increased kinetics of activation and relaxation, which underlie increased tension cost, i.e. increased ATP utilization for force development at the sarcomere level^{15–19}; and (iv) reduced super relaxed state of the cross-bridges, which will increase ATP utilization at low diastolic cytosolic calcium levels.²⁰ Evidence for a mutation-induced reduction in the efficiency of cardiac performance in asymptomatic mutation carriers comes from imaging studies combining [¹¹C]-acetate positron emission tomography and cardiovascular magnetic resonance imaging to assess myocardial external efficiency (MEE, i.e. the amount of oxygen used for cardiac work).^{18,21,22} These studies revealed reduced MEE in mutation carriers, indicating that inefficient cardiac contractility precedes the development of hypertrophy. Thus, recent *ex vivo* and *in vivo* analyses support the paradigm proposed by Ashrafian *et al.*²³ that energy depletion causes HCM.

2. Linking inefficient sarcomere contraction with metabolic changes

Energy depletion induced by increased ATP utilization for sarcomere contraction is expected to impair cellular mechanisms regulating Ca^{2+} homeostasis and metabolism. Increased diastolic Ca^{2+} levels have been reported in HCM mouse models and human HCM patient samples,^{19,24} indicating impaired Ca^{2+} handling. In addition, a reduced PCr (phosphocreatine)/ATP ratio was observed in HCM with and without hypertrophy indicating deficits in cardiac energetics at an early stage of HCM.²⁵ In the healthy heart, creatine kinase (CK) catalyses the transfer of phosphate from PCr to adenosine diphosphate (ADP), thereby regenerating ATP, while preventing accumulation of cytosolic ADP (Figure 1). Reducing PCr or experimental inhibition of CK activity has been causally linked to the development of heart failure, as it elevates left ventricle end-diastolic pressure (i.e. diastolic dysfunction), reduces contractility and increases mortality in rats.^{26–28} The consequence of low PCr and/or a reduced CK activity is that cytosolic levels of ADP will increase. Increases in (ADP) of >50% have been reported in HCM mouse models.^{16,29} Selectively increasing ADP levels without altering cytosolic ATP levels has been shown to limit myocardial relaxation in rats.³⁰ High ADP levels impair relaxation of wild-type rat hearts via ADP-mediated defects in sarcomere function.³¹ Moreover, ADP increased myofilament Ca^{2+} -sensitivity in human HCM samples.³² Thus, enhanced Ca^{2+} -sensitivity is

caused directly by the mutation and indirectly via increased ADP levels (Figure 2). These studies support the idea that energy depletion results in elevations of ADP, thereby causes diastolic dysfunction.

3. Mitochondrial dysfunction

Impaired sarcomere energetics also provokes mitochondrial dysfunction, increase reactive oxygen species (ROS) and lead to altered ion homeostasis and lethal arrhythmias.³³ Increased binding of Ca^{2+} to the myofilaments (via increased Ca^{2+} -sensitivity) will reduce the Krebs cycle activity. At the same time, high ATP utilization increases ADP, which will reduce the levels of NADH and NADPH, thereby triggers oxidative stress. The composition of intracellular metabolic substrates is essential to regulate ATP production and limit production of ROS by the mitochondria. In mitochondria, ADP accelerates ATP production via oxidation of NADH to NAD^+ . At the same time Ca^{2+} stimulates the Krebs cycle (conversion of NAD^+ to NADH) to match the ADP-mediated reduction in NADH, thereby maintaining the NADH/ NAD^+ redox state.^{34,35} The mutation-induced increase in myofilament Ca^{2+} -sensitivity will enhance ATP utilization and increase ADP levels. The increase in ADP will increase oxidation of both NADH and NADPH and perturb the NADH/ NAD^+ balance.³⁶ As NADPH is needed to detoxify ROS, the ADP-mediated NADPH oxidation will reduce the mitochondrial capacity to lower ROS. Moreover, as more Ca^{2+} will be bound to the sarcomeres due to the increased Ca^{2+} -sensitivity, less Ca^{2+} will be available to stimulate the mitochondrial Krebs cycle and regenerate NADH. Through these mechanisms, impaired sarcomere energetics may thus provoke mitochondrial dysfunction and increase ROS.

4. Vascular endothelial dysfunction and rarefaction

While inefficient sarcomere contraction and relaxation will increase energy demand of the heart, pathogenic vascular remodelling may disrupt energy supply. HCM patients have abnormal myocardial perfusion reserve, which is more pronounced in the endocardium vs. mid and epicardial layers. Reduced cardiac perfusion has been reported in HCM patients, which was most severe in patients with a sarcomere mutation.^{37,38} No microvascular dysfunction was observed in asymptomatic mutation carriers.²¹ The observation of reduced coronary flow reserve in HCM patients with normal coronary angiograms led to the concept of microvascular (endothelial) dysfunction as secondary pathomechanism in HCM development.^{39,40} Blunted coronary flow in response to adenosine (i.e. endothelial dysfunction) has been observed in hypertrophied and non-hypertrophied regions of the heart.⁴⁰ These studies suggest that mutation-induced cardiac contractile dysfunction precedes and possibly causes vascular (endothelial) dysfunction, which subsequently initiates remodelling (hypertrophy) of the heart. The inability of the capillary network to match the hypertrophic and disarrayed myocardium increases proportionately with the measured wall thickness on cardiac imaging, i.e. the most hypertrophic segments have the poorest perfusion reserve.^{41,42} Histological analysis revealed reduced capillary density (i.e. rarefaction) in septal tissue samples from patients with obstructive HCM.⁴³ A significant proportion of patients with HCM progress to develop myocardial replacement fibrosis, typically located within the area of maximal wall hypertrophy. The presence of fibrosis appears to predict those phenotypes that later progress onto heart failure⁴⁴ or are more likely to develop malignant ventricular arrhythmias.⁴⁵




Figure 1 Excitation-contraction coupling in a healthy heart. Contraction is initiated upon Ca^{2+} entry in the muscle cell, which activates Ca^{2+} release from the SR. Ca^{2+} binds to the myofilaments, which causes contraction. To relax Ca^{2+} detaches from myofilaments and is pumped back into the SR. A small fraction of Ca^{2+} is removed out of the cell via the Na^+ - Ca^{2+} exchanger (NCX). Mitochondria take care of sufficient ATP needed for proper contraction and relaxation of cardiomyocytes. In the healthy heart, CK catalyses the transfer of phosphate from phosphocreatine to ADP, thereby regenerating ATP, while preventing accumulation of cytosolic ADP.




Figure 2 Excitation-contraction coupling in diseased heart and possible targets for therapy. Mutation-induced changes in myofilament properties increase ATP utilization. Cellular metabolism changes as a consequences of mutation-induced and ADP-mediated increases in myofilament Ca^{2+} -sensitivity, impaired mitochondrial function and reduced creatine kinase activity. Different therapies may target impaired metabolism in HCM.

5. Changes in substrate metabolism in hypertrophied muscle

The healthy heart has a wide substrate versatility because it is able to metabolize fatty acids, carbohydrates, lactate, ketone bodies, and specific amino acids.⁴⁶ In normal condition, cardiomyocytes generate more than two-thirds of the ATP by the oxidation of fatty acids and the remainder one-third by the oxidation of other substrates such as glucose. Interestingly, though, the oxidation of glucose is more energy efficient than that of fatty acids (ATP/O ratio = 3.17 for glucose vs. ± 2 to 2.5 for fatty acids). In the case of acute increases in cardiac load, rapid supply of ATP is guaranteed by several mechanisms: increase in coronary flow and in oxygen extraction from the arterial coronary blood, and a metabolic shift from fatty acid oxidation to glucose oxidation (the Randle cycle). This 'glucose-fatty acid cycle' is a homeostatic mechanism that controls fuel selection and adapts substrate supply and demands in normal tissues and in the blood.⁴⁷ This shift from fatty acid oxidation to increased glucose metabolism is common in end-stage heart failure.⁴⁸ As a consequence, fatty acids and their derivatives accumulate into cells, causing lipotoxicity,⁴⁹ while glucose oxidation increases. This shift occurs mostly in mitochondria ('aerobic glycolysis' by oxidation of pyruvate) in order to guarantee more energy for the energy depleted failing heart. However, in failing hearts, a large part of glucose is converted to lactate through anaerobic glycolysis, which is less energy efficient. In the heart, it is possible that the latter process is the result of relative hypoxia caused by a reduced capillary density in combination with a higher workload of the hypertrophied heart. Recent findings indicate a central role for dihydrolipoyl succinyltransferase (DLST), the E2 subcomponent of the α -ketoglutarate dehydrogenase complex, a rate-controlling tri-carboxylic acid cycle enzyme, in cardiac oxidative metabolism and hypertrophy. Its decrease in the diseased heart parallels a reduction of oxidative metabolism, whereas its cardiac overexpression improves oxidative metabolism and protects against cardiac hypertrophy and dysfunction.⁵⁰

6. Atrial fibrillation

A high incidence of atrial fibrillation (AF) is observed in HCM, which worsens ventricular function. HCM patients with paroxysmal AF show reduced exercise capacity and is associated with markedly increased risk of death by stroke and heart failure.^{51,52} Moreover, AF is associated with advanced disease progression in HCM patients.⁵² AF may be caused by atrial dilatation in response to diastolic ventricular dysfunction. However, it may also involve a direct effect of the mutant protein on atrial myocyte function. A study in zebrafish harbouring an atrial-specific myosin light chain (*MYL4*) mutation, which was associated with early-onset AF in human, showed disrupted sarcomere structure, atrial enlargement and AF-like electrical abnormalities.⁵³ However, not all HCM sarcomere mutations are expressed in atrial cardiomyocytes. In a recent clinical study, no significant correlations were found between genotype and onset or severity of AF in a HCM cohort with mutations in *MYBPC3*, *MYH7* and 'other genotypes' (including thin filament gene mutations *TNNT2*, *TNNI3*, *TPM1*, and *MYL2* and Z-line).⁵⁴ Based on the latter study, the authors proposed that intrinsic atrial myopathy may be caused by rare (atrial-specific) mutations. If sarcomere mutations directly alter functional and structural properties of atrial cardiomyocytes warrants further experimental studies.

7. Non-myocyte compartment of the hypertrophied heart

The pathophysiology of HCM is not limited to sarcomere defects *within* cardiomyocytes but is also characterized by structural alterations in cardiomyocytes and the non-myocyte compartment of the heart. In a healthy heart, $\sim 70\%$ of the cardiomyocyte volume consists of myofibrils. This fraction is reduced in manifest human HCM, and largely explains the decreased cardiomyocyte maximal force generation capacity observed in HCM biopsies.⁵⁵ Cardiomyocytes solely account for 25–35% of all heart cells, while the non-myocyte populations are predominant and consist mostly of endothelial cells and cardiac fibroblasts.⁵⁶ Studies in HCM mice identified the pro-fibrotic transforming growth factor beta (TGF- β), most likely released from cardiac fibroblasts, as the main determinant of non-myocyte proliferation and myocardial fibrosis observed in HCM.⁵⁷ Since cardiac fibroblasts are responsible for extracellular matrix maintenance, and thus bridge biomechanical forces *to* and *from* cardiomyocytes, it has been speculated that the high basal myocardial activation observed in HCM cardiomyocytes (i.e. exacerbated biomechanical forces) is transmitted to the non-myocyte population, leading to increased expression of pro-fibrotic TGF- β .⁵⁸ This is supported by *ex vivo* culture studies of both cardiac fibroblasts and cardiomyocytes that showed increased expression of TGF- β following repetitive stretch procedures.^{59,60} Early manifestation of myocardial fibrosis is a hallmark of HCM and correlates well with the degree of hypertrophy, diastolic dysfunction and energy consumption,^{44,61} indicating that targeting the extracellular matrix via TGF- β may represent a way to modify disease progression.

8. Therapies

8.1 Targeting metabolism

On the basis of the consideration that inhibition of mitochondrial fatty acid oxidation leads to cardiac hypertrophy, a study in rats has recently shown that the restoration of fatty acid metabolism confers beneficial effects on the hypertrophic heart.⁶² CD36-deficient (Cluster of differentiation 36, a major sarcolemmal fatty acid transporter) spontaneously hypertensive rats with established hypertrophy were treated with Tricaprylin, a triglyceride of caprylic acid, that stimulates fatty acid oxidation and maintains the cellular redox status. This treatment decreased cardiomyocyte cross-sectional area and reduced interstitial fibrosis, along decreased expression of BNP, calcineurin A and oxidative stress biomarkers. Cardiac function and energetics were also influenced by substrate availability. In fact, fenofibrate treatment in the absence of the appropriate metabolic substrate resulted in the mobilization of endogenous triglycerides and caused an imbalance of the cellular redox status, leading to enhanced free radical production and adverse cardiac changes. Conversely, medium-chain triglycerides have the capacity to bypass CD36 and serve as substrate for fatty acid oxidation,⁶³ maintaining the intracellular redox status. Perhexiline is a metabolic drug which shifts metabolism away from the preferred fatty acids toward carbohydrates, and would thereby increase ATP supply. Perhexiline treatment enhanced glycolysis and protected against catecholamine-induced cardiac damage in a mouse model of peripartum cardiomyopathy.⁶⁴

Metabolic remodelling appears to be reversible as regression of left ventricular hypertrophy is preceded by improved cardiac energy metabolism, as indicated in a mouse study of aortic constriction surgery

followed by debanding.⁶⁵ Debanding—unloading of the hyperpertrophic heart—significantly reduced left ventricular mass and wall thickness, along with profound changes in transcripts and proteins of cardiac substrate metabolism. However, debanding did not normalize the transcripts of proteins regulating glucose and fatty acid metabolism. This paradox is likely explained by the fact that cardiac energy metabolism is regulated at multiple levels, including many post-translational modifications. These data agree with the only partial reversal of depressed metabolic gene expression in the failing heart after implantation of a left ventricular assist device.⁶⁶ Likewise, aortic valve replacement surgery in patients with aortic valve stenosis increased MEE, but MEE was not corrected to control values 4 months after surgery.⁶⁷ Although only partial correction of MEE was observed, the improvement of MEE closely correlated with increased exercise capacity.⁶⁷ These studies involve a hemodynamic, non-genetic overload of the heart, and may not translate to genetic forms of HCM. However, therapy targeting metabolism may be effective in HCM. Perhexiline treatment of HCM mice harbouring a *MYBPC3* mutation improved some features of the HCM phenotype (reduced cardiac mass), which was associated with metabolic changes.⁶⁸ Treatment of symptomatic HCM patients with improved exercise capacity.⁶⁹ The therapeutic benefit of perhexiline may be the resultant of its multiple pleiotropic actions.⁷⁰ Far from inducing a simple shift from fatty acid to glucose oxidation, perhexiline may cause complex rebalancing of carbon and nucleotide phosphate fluxes to increase metabolic flexibility and to maintain cardiac output.⁷¹ The benefit of metabolic drug therapy may depend on the ability of the heart to shift from mitochondrial lipid to glucose oxidation. As described above, hypertrophied hearts shift their metabolism from fatty acids to glucose utilization and glycolytic metabolism in an attempt to optimize energetic status.⁷² Mitochondrial oxidative metabolism decreases, while glycolysis as an alternate source of ATP production increases. Accordingly, *in vivo* imaging studies in advanced HCM patients suggest that metabolism shifted to the lower oxygen consuming glucose metabolism.²² Though initially adaptive, in the long run the (chronic) metabolic shift is detrimental for the heart as increased glycolysis increases pyruvate and lactate. The latter is accompanied by accumulation of H^+ in the cytosol, which eventually leads to elevated calcium (i.e. impaired relaxation).⁷² While several pathways are activated in the severe (hypertrophic) stage of disease as compensatory mechanism, paradoxically, chronic stimulation of these pathways is detrimental. Likewise, chronic metabolic therapy may be harmful for the heart. Based on positive effects of exercise in cardiac disease, which is intermittent by its very nature, one may consider if intermittent metabolic drug-therapy, as opposed to chronic drug-treatment, represents a more effective and novel approach to treat cardiomyopathy.

Noteworthy, combined proteomics and metabolomics analysis revealed impaired energy generating pathways in mice with very high creatine levels that subsequently develop cardiac hypertrophy and dysfunction. Overall, these studies indicate that either low or very high levels of creatine perturb cardiac performance, and suggests that there is a therapeutic window of optimizing the cardiac energy balance in the heart.⁷³

In conclusion, the hypertrophied and failing heart shows several metabolic changes. Improving the efficiency of energy generation in the hypertrophied heart can be exploited in order to optimize specific therapies. Metabolic alterations are (partially) reversible and their early identification may represent a therapeutic option (Figure 2).

8.2 Stimulation of β_3 -adrenergic receptors

Activation of β_3 -adrenergic receptors (β_3 AR) may be a way to modify altered energetic status of the HCM heart. β_3 AR are expressed in human cardiac myocytes and endothelial cells.^{74,75} They differ from the other two β AR isotypes in a number of ways; (i) in cardiac muscle, they exert effects that are antipathetic to those of $\beta_{1,2}$ AR on contractility (i.e. they act as “endogenous $\beta_{1,2}$ AR blockers”)⁷⁴; (ii) β_3 AR expression increases in cardiac myocytes from diseased including failing hearts⁷⁴; (iii) β_3 AR lack consensus sequences for phosphorylation by GRK2 or protein kinase A (PKA) in their C-terminal tail, which attenuates or suppresses their desensitization, depending on the cell context.⁷⁶ These characteristics make β_3 AR attractive targets in the context of heart failure, a condition with prevailing hyperadrenergism, when $\beta_{1,2}$ AR usually are desensitized/downregulated. Reduced β_1 AR signalling has also been observed in human HCM evident from reduced PKA-mediated phosphorylation of sarcomeric target proteins.^{12,14} Decreased PKA-mediated phosphorylation of troponin I (TnI) causes increased myofilament Ca^{2+} -sensitivity, which will further exacerbate the energetic defect in HCM. In human cardiac muscle, β_3 AR couple through G-alpha-i to activation of the constitutive nitric oxide synthase (NOS),⁷⁷ endothelial NOS and neuronal NOS (nNOS), both expressed in cardiac myocytes.⁷⁸ β_3 AR expression and activity correlates with tonic increases in cGMP.⁷⁷ Downstream activation of cGMP-dependent kinase (PKG)-I-alpha is expected to phosphorylate a number of targets functionally relevant to both excitation-contraction coupling and cardiac muscle remodelling. PKG modulates phospholamban phosphorylation to increase Ca^{2+} reuptake in the sarcoplasmic reticulum (SR),⁷⁹ resulting in improved diastolic relaxation as well as increased SR load. PKG phosphorylates TnI to decrease myofilament Ca^{2+} -sensitivity (Figure 2).⁸⁰ PKG also modulates the phosphorylation of titin on specific residues, with putative improvements in myocyte elastic properties.⁸¹ nNOS also modulates PKA-mediated phospholamban phosphorylation and improves Ca^{2+} reuptake in the SR through cGMP-independent effects on protein phosphatase.⁸²

These effects should directly improve relaxation and decrease myofilament Ca^{2+} -sensitivity, with expected beneficial effects on energetics in HCM. In addition, β_3 AR uniquely exert antioxidant properties in hypertrophic cardiac muscle.^{83,84} This may counteract the adverse pro-oxidant consequences of increased ADP and decreased Ca^{2+} uptake by mitochondria. In addition, activation of the β_3 AR/NOS/cGMP pathway attenuates hypertrophic remodelling in several mouse models of neuro-hormonal or hemodynamic overload.^{78,83,85} Fibrosis is also decreased, through β_3 AR modulation of paracrine signalling from cardiac myocytes to fibroblasts, e.g. secondary to β_3 AR/nNOS anti-oxidant effects.⁸³ Coronary perfusion is also expected to be improved, as β_3 AR expressed in human coronary microvascular endothelial cells are coupled to both nitric oxide and EDHF-dependent relaxations,⁷⁵ as well as pro-angiogenic effects.⁸⁶ Finally, systemic activation of β_3 AR in beige/brown fat may add indirect metabolic effects through increased lipolysis and improved systemic insulin sensitivity.⁸⁷ Direct effects on cardiac metabolism, i.e. on the selection of energetic fuels (lipids versus glucose), particularly in the stressed or failing heart, are currently being studied.

8.3 Targeting myosin

An alternative way to modify cardiac contraction is the use of small molecules which directly target myosin. Omecamtiv mercabil (OM), a myosin activator is currently tested in clinical trials in patients with systolic heart failure.⁸⁸ While a myosin activator may increase cardiac contractile performance, it may come at the expense of increased cardiac oxygen

consumption as the compound may also increase myosin ATPase activity.⁸⁹ Interestingly, a recent study showed that OM increases contractility at $[Ca^{2+}]_i$, which are close to values at systole under basal conditions, while it decreased force at high (maximal) Ca^{2+} activation.⁹⁰ The latter study showed that the effect of OM depends on the concentration of both OM and intracellular Ca^{2+} levels, and the authors indicated that OM may be used to increase contractility and enhance function of a failing heart, while it may be used to reduce contractility in diastolic failure as observed in HCM dependent on its activating and inhibitory actions, respectively. A myosin inhibitor (mevacamten, also known as MYK-461), which was shown to reduce contractility,⁹¹ and most likely reduces oxygen consumption of the hypertrophied heart, suppressed HCM in a mouse models with *MYH7* mutations.⁹² MYK-461 is currently tested in HCM by Myocardia. The use of myosin activators and inhibitors is an attractive novel approach to correct cardiac dysfunction, thereby influence metabolism.

8.4 Genetic interventions

Recently, a novel role was identified for microRNA-146a in regulating cardiac metabolism via suppression of oxidative metabolism.⁵⁰ MicroRNA-146a targets a key component of the α -ketoglutarate dehydrogenase complex named DLST. Overexpression of DLST or inhibition of microRNA-146a blunted the hypertrophic response upon pressure overload in mice, which coincided with partial maintenance of oxidative metabolism. Increased miRNA-146a has been linked with reduced cardiac *erbb4* signalling, which is central in regulating glucose metabolism.⁹³ While inhibition of microRNA-146a may directly improve metabolism of cardiac muscle, energy supply may be improved via modulation of cardiac perfusion. MiRNAs may thus represent targets to improve metabolism and energy supply of the hypertrophied heart. In addition, mitochondrial-derived non-coding RNAs that are likely involved in metabolic processes have recently been found in patients with myocardial infarction and may be useful biomarkers of cardiac diseases and/or prognostic markers.⁹⁴

9. Conclusion

Studies in mice and human have indicated that metabolic changes in development of HCM may represent an attractive therapeutic target. Recent studies in HCM mouse models and human cardiac biopsies emphasized that, although the final clinical HCM phenotype may be independent of genotype, the initial mutation-induced defects in sarcomere function^{11,15,16} and subsequent changes in signalling pathways⁹⁵ may significantly differ based on the affected gene and even based on the specific mutation. This emphasizes the need to study the early mutation-induced changes in mitochondrial and metabolic pathways, which will aid in the development of patient-tailored (mutation-tailored) preventive therapies.

Conflict of interest: T.T. filed and licensed patents on cardiac non-coding RNAs. T.T. is founder of Cardior Pharmaceuticals. M.M. filed and licensed patents on non-coding RNAs as biomarkers. And all others have none to declare.

Funding

J.V. is supported by the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2014-40 DOSIS. S.H. has received funding from the European Union Commission's

Seventh Framework programme under grant agreement N° 305507 (HOMAGE), N° 602904 (FIBROTARGETS) and FP7-Health-2013-Innovations-1 N° 602156 (HECATOS). We acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2011-ARENA, CVON2016-Early HFPEF, 2015-10, and CVON ShePREDICTS, grant 2017-21. This research is co-financed as a PPP-allowance Research and Innovation by the Ministry of Economic Affairs within Top Sector Life sciences & Health. This research was co-funded by the C3 project 'Vision Core Leuven' of the Leuven University. C.G.T. is supported by a Federico II University "Ricerca di Ateneo" grant. T.T. received funding from the European Research Area Network on Cardiovascular Diseases (ERA-CVD), Project EXPERT. J.-L.B. funded by grants from the Fonds National de la Recherche Scientifique (FNRS; PDR T.0144.13), European Union (UE LSHM-CT-05-018833, "beta3lvh"), and the Federation Wallonie-Bruxelles (Action de Recherche Concertée ARC11-16/035). Funding of A.F.L.-M. and I.F.-P.: Project DOCnet (NORTE-01-0145-FEDER-000003), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and the project NETDIAMOND (POCI-01-0145-FEDER-016385), supported by European Structural and Investment Funds, Lisbon's Regional Operational Program 2020 and Portuguese funds from the Portuguese Foundation for Science and Technology.

References

- Maack C, Murphy E. Metabolic cardiomyopathies—fighting the next epidemic. *Cardiovasc Res* 2017;**113**:367–369.
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;**65**:1249–1254.
- Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Tein Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'Rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL, Klein WW, Priori SG, Alonso-Garcia A, Blomström-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *J Am Coll Cardiol* 2003;**42**:1687–1713.
- Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. *N Engl J Med* 1989;**321**:1372–1378.
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. *Cell* 1990;**62**:999–1006.
- Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric cardiomyopathies: state of the art. *Cardiovasc Res* 2015;**105**:397–408.
- Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, Watkins H, Reggiani C. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed *in vivo* and associated with an increased calcium sensitivity. *Circ Res* 1998;**82**:106–115.
- Morimoto S, Yanaga F, Minakami R, Ohtsuki I. Ca^{2+} -sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. *Am J Physiol* 1998;**275**:C200–C207.
- Takahashi-Yanaga F, Morimoto S, Harada K, Minakami R, Shiraishi F, Ohta M, Lu QW, Sasaguri T, Ohtsuki I. Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. *J Mol Cell Cardiol* 2001;**33**:2095–2107.
- Morimoto S, Lu QW, Harada K, Takahashi-Yanaga F, Minakami R, Ohta M, Sasaguri T, Ohtsuki I. Ca^{2+} -desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. *Proc Natl Acad Sci USA* 2002;**99**:913–918.
- Robinson P, Griffiths PJ, Watkins H, Redwood CS. Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. *Circ Res* 2007;**101**:1266–1273.
- van Dijk SJ, Paalberends ER, Najafi A, Michels M, Sadayappan S, Carrier L, Boontje NM, Kuster DW, van Slegtenhorst M, Dooijes D, dos Remedios C, ten Cate FJ,

- Stienen GJ, van der Velden J. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. *Circ Heart Fail* 2012;**5**:36–46.
13. Miller T, Szczesna D, Housmans PR, Zhao J, de Freitas F, Gomes AV, Culbreath L, McCue J, Wang Y, Xu Y, Kerrick WG, Potter JD. Abnormal contractile function in transgenic mice expressing a familial hypertrophic cardiomyopathy-linked troponin T (I79N) mutation. *J Biol Chem* 2001;**276**:3743–3755.
14. Sequeira V, Wijinker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M, van der Velden J. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. *Circ Res* 2013;**112**:1491–1505.
15. Witjas-Paalberends ER, Ferrara C, Scellini B, Piroddi N, Montag J, Tesi C, Stienen GJ, Michels M, Ho CY, Kraft T, Poggesi C, van der Velden J. Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation. *J Physiol* 2014;**592**:3257–3272.
16. Spindler M, Saue KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, Ingwall JS. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. *J Clin Invest* 1998;**101**:1775–1783.
17. Chandra M, Tschirgi ML, Tardiff JC. Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation. *Am J Physiol Heart Circ Physiol* 2005;**289**:H2112–H2119.
18. Witjas-Paalberends ER, Güçlü A, Germans T, Knaepen P, Harms HJ, Vermeer AM, Christiaans I, Wilde AA, Dos Remedios C, Lammertsma AA, van Rossum AC, Stienen GJ, van Slegtenhorst M, Schinkel AF, Michels M, Ho CY, Poggesi C, van der Velden J. Gene-specific increase in energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. *Cardiovasc Res* 2014;**103**:248–257.
19. Ferrantini C, Coppini R, Pioner JM, Gentile F, Tosi B, Mazzoni L, Scellini B, Piroddi N, Laurino A, Santini L, Spinelli V, Sacconi L, De Tompe P, Moore R, Tardiff J, Mugelli A, Olivetto I, Cerbai E, Tesi C, Poggesi C. Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: a comparison of the cardiac troponin T E163R and R92Q mouse models. *J Am Heart Assoc* 2017;**6**:e005407.
20. McNamara JW, Li A, Lal S, Bos JM, Harris SP, van der Velden J, Ackerman MJ, Cooke R, dos Remedios CG. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. *PLoS One* 2017;**12**:e0180064.
21. Timmer SA, Germans T, Brouwer WP, Lubberink M, van der Velden J, Wilde AA, Christiaans I, Lammertsma AA, Knaepen P, van Rossum AC. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. *Eur J Heart Fail* 2011;**13**:1283–1289.
22. Güçlü A, Knaepen P, Harms HJ, Parbhudayal RY, Michels M, Lammertsma AA, van Rossum AC, Germans T, van der Velden J. Disease stage-dependent changes in cardiac contractile performance and oxygen utilization underlie reduced myocardial efficiency in human inherited hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging* 2017;**10**:e005604.
23. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. *Trends Genet* 2003;**19**:263–268.
24. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivetto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. *Circulation* 2013;**127**:575–584.
25. Crilly JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. *J Am Coll Cardiol* 2003;**41**:1776–1782.
26. Hamman BL, Bittl JA, Jacobus WE, Allen PD, Spencer RS, Tian R, Ingwall JS. Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. *Am J Physiol* 1995;**269**:H1030–H1036.
27. Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. *Circulation* 1997;**96**:1313–1319.
28. Horn M, Remkes H, Strömer H, Dienesch C, Neubauer S. Chronic phosphocreatine depletion by the creatine analogue β -guanidinopropionate is associated with increased mortality and loss of ATP in rats after myocardial infarction. *Circulation* 2001;**104**:1844–1849.
29. He H, Javadpour MM, Latif F, Tardiff JC, Ingwall JS. R-92L and R-92W mutations in cardiac troponin T lead to distinct energetic phenotypes in intact mouse hearts. *Biophys J* 2007;**93**:1834–1844.
30. Tian R, Christe ME, Spindler M, Hopkins JC, Halow JM, Camacho SA, Ingwall JS. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. *J Clin Invest* 1997;**99**:745–751.
31. Sequeira V, Najafi A, McConnell M, Fowler ED, Bollen IAE, Wüst RCI, Dos Remedios CG, Helmes M, White E, Stienen GJ, Tardiff JC, Kuster DW, van der Velden J. Synergistic role of ADP and Ca^{2+} in diastolic myocardial stiffness. *J Physiol* 2015;**593**:3899–3916.
32. Sequeira V, Najafi A, Wijinker PJ, Dos Remedios CG, Michels M, Kuster DW, van der Velden J. ADP-stimulated contraction: a predictor of thin-filament activation in cardiac disease. *Proc Natl Acad Sci USA* 2015;**112**:E7003–E7012.
33. Wijinker PJ, Sequeira V, Kuster DW, van der Velden J. Hypertrophic cardiomyopathy: a vicious cycle triggered by sarcomere mutations and secondary disease hits. *Antiox Redox Signal* 2018; doi:10.1089/ars.2017.7236.
34. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. *J Mol Cell Cardiol* 2002;**34**:1259–1271. Review.
35. Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O'Rourke B. Elevated cytosolic Na^{+} decreases mitochondrial Ca^{2+} uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. *Circ Res* 2006;**99**:172–182.
36. Nickel AG, von Hardenberg A, Hohl M, Löffler JR, Kohlhaas M, Becker J, Reil JC, Kazakov A, Bonnekoh J, Stadelmaier M, Puhl SL, Wagner M, Bogeski I, Cortassa S, Kappl R, Pasioka B, Lafontaine M, Lancaster CR, Blacker TS, Hall AR, Duchon MR, Kästner L, Lipp P, Zeller T, Müller C, Knopp A, Laufs U, Böhm M, Hoth M, Maack C. Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. *Cell Metab* 2015;**22**:472–484.
37. Olivetto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, Nistri S, Sgalambro A, Grifoni C, Torricelli F, Camici PG, Cecchi F. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofibrillar gene mutations. *J Am Coll Cardiol* 2011;**58**:839–848.
38. Camici PG, Olivetto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. *J Mol Cell Cardiol* 2012;**52**:857–864.
39. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. *Circulation* 2007;**115**:2418–2425.
40. Olivetto I, d'Amati G, Basso C, Van Rossum A, Patten M, Emdin M, Pinto Y, Tomberli B, Camici PG, Michels M. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. *Cardiovasc Res* 2015;**105**:409–423.
41. Ismail TF, Hsu L-Y, Greve AM, Gonçalves C, Jabbour A, Gulati A, Hewins B, Mistry N, Wage R, Roughton M, Ferreira PF, Gatehouse P, Firmin D, O'Hanlon R, Pennell DJ, Prasad SK, Arai AE. Coronary microvascular ischemia in hypertrophic cardiomyopathy—a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. *J Cardiovasc Magn Reson* 2014;**16**:49.
42. Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ, de Silva R, Hsu LY, Greve AM, Nijjer S, Broyd C, Ali A, Keegan J, Francis DP, Davies JE, Hughes AD, Arai A, Frenneaux M, Stables RH, Di Mario C, Prasad SK. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. *J Am Coll Cardiol* 2016;**68**:1651–1660.
43. Güçlü A, Happé C, Eren S, Korkmaz IH, Niessen HW, Klein P, van Slegtenhorst M, Schinkel AF, Michels M, van Rossum AC, Germans T, van der Velden J. Left ventricular outflow tract gradient is associated with reduced capillary density in hypertrophic cardiomyopathy irrespective of genotype. *Eur J Clin Invest* 2015;**45**:1252–1259.
44. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaiibeek L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;**56**:867–874.
45. Dawson DK, Hawlisch K, Prescott G, Roussin I, Di Pietro E, Deac M, Wong J, Frenneaux MP, Pennell DJ, Prasad SK. Prognostic role of CMR in patients presenting with ventricular arrhythmias. *JACC Cardiovasc Imaging* 2013;**6**:335–344.
46. Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M. Metabolic support for the heart: complementary therapy for heart failure? *Eur J Heart Fail* 2016;**18**:1420–1429.
47. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. *Am J Physiol Endocrinol Metab* 2009;**297**:E578–E591.
48. Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. *Cardiovasc Res* 2011;**90**:202–209.
49. Sharma S, Adroge JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. *FASEB J* 2004;**18**:1692–1700.
50. Heggermont WA, Papageorgiou AP, Quaegebeur A, Deckx S, Carai P, Verheesen W, Eelen G, Schoors S, van Leeuwen R, Alekseev S, Elzenaar I, Vinckier S, Pokreisz P, Walravens AS, Gijbbers R, Van Den Haute C, Nickel A, Schroen B, van Bilsen M, Janssens S, Maack C, Pinto Y, Carmeliet P, Heymans S. Inhibition of microRNA-146a and overexpression of its target dihydrolipoyl succinyltransferase protect against pressure overload-induced cardiac hypertrophy and dysfunction. *Circulation* 2017;**136**:747–761.
51. Azarbal F, Singh M, Finocchiaro G, Le VV, Schnitger I, Wang P, Myers J, Ashley E, Perez M. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. *Heart* 2014;**100**:624–630.
52. Finocchiaro G, Haddad F, Knowles JW, Caleshu C, Pavlovic A, Homburger J, Shmargad Y, Sinagra G, Magavern E, Wong M, Perez M, Schnitger I, Myers J, Froelicher V, Ashley EA. Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. *JACC Heart Fail* 2015;**3**:408–418.
53. Orr N, Arnaout R, Gula LJ, Spears DA, Leong-Sit P, Li Q, Tarhuni W, Reischauer S, Chauhan VS, Borkovich M, Uppal S, Adler A, Coughlin SR, Stainier DY, Gollob MH. A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. *Nat Commun* 2016;**7**:11303.

54. Bongini C, Ferrantini C, Girolami F, Coppini R, Arretini A, Targetti M, Bardi S, Castelli G, Torricelli F, Cecchi F, Ackerman MJ, Padeletti L, Poggesi C, Olivetto I. Impact of genotype on the occurrence of atrial fibrillation in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 2016;**117**:1151–1159.
55. Witjas-Paalberends ER, Piroddi N, Stam K, van Dijk SJ, Sequeira V, Ferrara C, Scellini B, Hazebroek M, ten Cate FJ, van Slegtenhorst M, Dos Remedios CG, Niessen HW, Tesi C, Stienen GJ, Heymans S, Michels M, Poggesi C, van der Velden J. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. *Cardiovasc Res* 2013;**99**:432–441.
56. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA, Tallquist MD. Revisiting cardiac cellular composition. *Circ Res* 2016;**118**:400–409.
57. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Naylor M, Konno T, Gorham JM, Wolf CM, Kim JB, Schmitt JP, Molkentin JD, Norris RA, Tager AM, Hoffman SR, Markwald RR, Seidman CE, Seidman JG. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires $\text{tgf-}\beta$. *J Clin Invest* 2010;**120**:3520–3529.
58. Teekakirikul P, Padera RF, Seidman JG, Seidman CE. Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics. *J Cell Biol* 2012;**199**:417–421.
59. van Wamel AJ, Ruwof C, van der Valk-Kokshoorn LJ, Schrier PI, van der Laarse A. Stretch-induced paracrine hypertrophic stimuli increase TGF- β 1 expression in cardiomyocytes. *Mol Cell Biochem* 2002;**236**:147–153.
60. Ruwof C, van Wamel AE, Egas JM, van der Laarse A. Cyclic stretch induces the release of growth promoting factors from cultured neonatal cardiomyocytes and cardiac fibroblasts. *Mol Cell Biochem* 2000;**208**:89–98.
61. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J, Seidman CE. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. *N Engl J Med* 2010;**363**:552–563.
62. Saifudeen I, Subhadra L, Konnottl R, Renuka Nair R. Metabolic modulation by medium-chain triglycerides reduces oxidative stress and ameliorates CD36-mediated cardiac remodeling in spontaneously hypertensive rat in the initial and established stages of hypertrophy. *J Cardiac Fail* 2017;**23**:240–251.
63. Labarthe F, Khairallah M, Bouchard B, Stanley WC, Des Rosiers C. Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts on adrenergic stress: benefits of a medium-chain fatty acid. *Am J Physiol* 2005;**288**:H1425–H1436.
64. Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, Silvola JM, Roivainen A, Saraste A, Nickel AG, Saar JA, Sieve I, Pietzsch S, Müller M, Bogeski I, Kappl R, Jauhiainen M, Thackeray JT, Scherr M, Bengel FM, Hagl C, Tudorache I, Bauersachs J, Maack C, Hilfiker-Kleiner D. Low STAT3 expression sensitizes to toxic effects of β -adrenergic receptor stimulation in peripartum cardiomyopathy. *Eur Heart J* 2017;**38**:349–361.
65. Byrne NJ, Levasseur J, Sung MM, Masson G, Boisvenue J, Young ME, Dyck JR. Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression. *Cardiovasc Res* 2016;**110**:249–257.
66. Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeier h. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. *Circulation* 2002;**106**:407–411.
67. Güçlü A, Knaepen P, Harms HJ, Vonk AB, Stooker W, Groepenhoff H, Lammertsma AA, van Rossum AC, Germans T, van der Velden J. Myocardial efficiency is an important determinant of functional improvement after aortic valve replacement in aortic valve stenosis patients: a combined PET and CMR study. *Eur Heart J Cardiovasc Imaging* 2015;**16**:882–889.
68. Gehmlich K, Dodd MS, Allwood JW, Kelly M, Bellahcene M, Lad HV, Stockenhuber A, Hooper C, Ashrafian H, Redwood CS, Carrier L, Dunn WB. Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. *Mol Biosyst* 2015;**11**:564–573.
69. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. *Circulation* 2010;**122**:1562–1569.
70. George CH, Mitchell AN, Preece R, Bannister ML, Yousef Z. Pleiotropic mechanisms of action of perhexiline in heart failure. *Expert Opin Ther Pat* 2016;**26**:1049–1059.
71. Yin X, Dwyer J, Langley SR, Mayr U, Xing Q, Drozdov I, Nabeebaccus A, Shah AM, Madhu B, Griffiths J, Edwards LM, Mayr M. Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome. *J Mol Cell Cardiol* 2013;**55**:27–30.
72. de Jong KA, Lopaschuk GD. Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. *Can J Cardiol* 2017;**33**:860–871.
73. Zervou S, Yin X, Nabeebaccus AA, O'Brien BA, Cross RL, McAndrew DJ, Atkinson RA, Eykyn TR, Mayr M, Neubauer S, Lygate CA. Proteomic and metabolomic changes driven by elevating myocardial creatine suggest novel metabolic feedback mechanisms. *Amino Acids* 2016;**48**:1969–1981.
74. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. *Circulation* 2001;**103**:1649–1655.
75. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. *Circulation* 2004;**110**:948–954.
76. Liggett SB, Freedman NJ, Schwinn DA, Lefkowitz RJ. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. *Proc Natl Acad Sci USA* 1993;**90**:3665–1669.
77. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. *J Clin Invest* 1998;**102**:1377–1384.
78. Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Götz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL. Enhanced expression of β 3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. *Circulation* 2014;**129**:451–462.
79. Musialek P, Rigg L, Terrar DA, Paterson DJ, Casadei B. Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors. *J Mol Cell Cardiol* 2000;**32**:1831–1840.
80. Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E, Kass DA. PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. *Basic Res Cardiol* 2010;**105**:337–347.
81. Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, Dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. *Circ Res* 2009;**104**:87–94.
82. Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, El-Armouche A, Kranias EG, Casadei B. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. *Circ Res* 2008;**102**:242–249.
83. Hermida N, Michel L, Esfahani H, Dubois-Deruy E, Hammond J, Bouzin C, Markl A, Colin H, Steenbergen AV, De Meester C, Beauloye C, Horman S, Yin X, Mayr M, Balligand JL. Cardiac myocyte β 3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling. *Eur Heart J* 2018;**39**:888–898.
84. Bundgaard H, Liu CC, Garcia A, Hamilton EJ, Huang Y, Chia KK, Hunyor SN, Figtree GA, Rasmussen HH. β (3) adrenergic stimulation of the cardiac Na⁺+K⁺ pump by reversal of an inhibitory oxidative modification. *Circulation* 2010;**122**:2699–2708.
85. Vanhoutte L, Guilbaud C, Martherus R, Bouzin C, Gallez B, Dessy C, Balligand JL, Moniotte S, Feron O. MRI assessment of cardiomyopathy induced by β 1-adrenoceptor autoantibodies and protection through β 3-adrenoceptor overexpression. *Sci Rep* 2017;**7**:43951.
86. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL. Endothelial beta3-adrenoceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. *Circulation* 2005;**112**:1198–1205.
87. Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elia E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM. Activation of human brown adipose tissue by a β 3-adrenergic receptor agonist. *Cell Metab* 2015;**21**:33–38.
88. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvestre S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. *Science* 2011;**331**:1439–1443.
89. Bakkehaug JP, Kildal AB, Engstad ET, Boardman N, Næsheim T, Rønning L, Aasum E, Larsen TS, Myrmet T, How OJ. Myosin activator omecantiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity. *Circ Heart Fail* 2015;**8**:766–775.
90. Kampourakis T, Zhang X, Sun YB, Irving M. Omecantiv mecarbil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament. *J Physiol* 2018;**596**:31–46.
91. Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. *J Biol Chem* 2017;**292**:16571–16577.
92. Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, Song Y, Wan W, Leinwand LA, Spudis JA, McDowell RS, Seidman JG, Seidman CE. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. *Science* 2016;**351**:617–621.
93. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliva K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. *J Clin Invest* 2013;**123**:2143–2154.
94. Kumarswamy R, Bauters C, Volkman I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F, Thum T. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. *Circ Res* 2014;**114**:1569–1575.
95. Vakrou S, Fukunaga R, Foster DB, Sorensen L, Liu Y, Guan Y, Woldemichael K, Pineda-Reyes R, Liu T, Tardiff JC, Leinwand LA, Tocchetti CG, Abraham TP, O'Rourke B, Aon MA, Abraham MR. Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. *JCI Insight* 2018;**3**:94493.